In a nutshell
This study reviewed data on the association between dipeptidyl peptidase-4 (DPP4) inhibitors and cancer development in patients with type 2 diabetes. They found that patients receiving DPP4 inhibitors were not at a greater risk of developing cancer.
Some background
Management of type 2 diabetes requires stringent blood glucose (sugar) control. There are several strategies to achieve this. One strategy involves targeting a compound called glucagon-like peptide-1 (GLP-1). GLP-1 acts to reduce blood glucose via several mechanisms.
Dipeptidyl peptidase-4 (DPP4) inhibitors are a class of drugs that extend the activity of GLP-1 produced in the intestine. This aids in the regulation of blood glucose in patients with type 2 diabetes. As DPP4 inhibitors are a relatively new medication there has been some concern about potential long-term side effects.
Methods & findings
This study reviewed whether there is an association between DPP4 inhibitors and the development of cancer.
This study compared data from 72 clinical trials that included over 69,000 patients with type 2 diabetes. These patients were receiving DPP4 inhibitors, other anti-diabetes drugs or placebo (substance with no active effect). Rates of cancer and the risk associated with DPP4 inhibitor treatment was examined.
DPP4 inhibitor treatment was not associated with an increased risk of overall cancers. There was no association between DPP4 inhibitors and any specific type of cancer.
The bottom line
This study concluded that DPP4 inhibitors are not associated with an increased risk of cancer.
The fine print
As DPP4 inhibitors are a relatively new treatment, studies addressing any long-term effects will be necessary.
What’s next?
If you have any concerns regarding diabetes management and cancer risk please discuss this with your doctor.
Published By :
Scientific reports
Date :
Aug 15, 2017
